Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis

References

• Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472–1475.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
   PubMed Web of Science ®Google Scholar
• Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:339–348.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Bayraktar UD. No donor"? Consider a Haploidentical transplant. Blood Rev. 2015;29:63–70.
   PubMed Web of Science ®Google Scholar
• Tucunduva L, Ruggeri A, Sanz G, et al. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the acute leukemia Working Party of the European group for blood and marrow transplantation. Bone Marrow Transplant. 2014;49:887–894.
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Labopin M, Sanz G, et al. Comparison of outcomes after unrelated cord blood and unmanipulated Haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29:1891–1900.
   PubMed Web of Science ®Google Scholar
• Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–3073.
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–650.
   PubMed Web of Science ®Google Scholar
• Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–660.
   PubMed Web of Science ®Google Scholar
• Milano F, Gooley T, Wood B, et al. Cord-Blood transplantation in patients with Minimal Residual disease. N Engl J Med. 2016;375:944–953.
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-Haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13:132.
   PubMed Web of Science ®Google Scholar
• Huang XJ, Chang YJ. Unmanipulated HLA-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:197–204.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu QF, Xu LP, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125:3956–3962.
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang X, Jackson K, et al. Comparison of outcomes of hematopoietic cell transplants from T-replete Haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-matched unrelated donors and HLA-Identical sibling donors: A Multivariable analysis including disease risk Index. Biol Blood Marrow Transplant. 2016;22:125–133.
   PubMed Web of Science ®Google Scholar
• Han LJ, Wang Y, Fan ZP, et al. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2017;179:120–130.
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5, 211ra157.
   PubMed Web of Science ®Google Scholar
• Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010;47:65–77.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Solomon SR, Sizemore CA, Sanacore M, et al. Total Body Irradiation-based myeloablative Haploidentical stem cell transplantation Is a Safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015;21:1299–1307.
   PubMed Web of Science ®Google Scholar
• Rashidi A, DiPersio JF, Westervelt P, et al. Comparison of outcomes after peripheral blood Haploidentical versus matched unrelated donor Allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: A retrospective single-center review. Biol Blood Marrow Transplant. 2016;22:1696–1701.
   PubMed Web of Science ®Google Scholar
• Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using Haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938–947.
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-Haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310–1316.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–1040.
   PubMed Web of Science ®Google Scholar
• Martinez C, Gayoso J, Canals C, et al. Post-Transplantation cyclophosphamide-based Haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: A registry study of the lymphoma Working Party of the European Society for blood and marrow transplantation. J Clin Oncol. 2017;35:3425–3432.
   PubMed Web of Science ®Google Scholar
• Brissot E, Labopin M, Ehninger G, et al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the acute leukemia Working Party of the EBMT. Haematologica. 2019;104:524–532.
   PubMed Web of Science ®Google Scholar
• Pagliardini T, Harbi S, Furst S, et al. Post-transplantation cyclophosphamide-based Haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. Bone Marrow Transplant. 2019;54:1067–1076.
   PubMedGoogle Scholar
• Dreger P, Sureda A, Ahn KW, et al. PTCy-based Haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019;3:360–369.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Milton DR, Poon LM, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with Haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20:1975–1981.
   PubMed Web of Science ®Google Scholar
• Saini NY, Saliba RM, Rondon G, et al. Impact of donor type and Melphalan dose on Allogeneic transplantation outcomes for patients with lymphoma. Biol Blood Marrow Transplant. 2019;25:1340–1346.
   PubMedGoogle Scholar
• Raiola AM, Dominietto A, di Grazia C, et al. Unmanipulated Haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20:1573–1579.
   PubMed Web of Science ®Google Scholar
• Shem-Tov N, Peczynski C, Labopin M, et al. Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Leukemia. 2020;34:283–292.
   PubMed Web of Science ®Google Scholar
• Santoro N, Labopin M, Giannotti F, et al. Unmanipulated Haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11:55.
   PubMed Web of Science ®Google Scholar
• Piemontese S, Ciceri F, Labopin M, et al. A comparison between allogeneic stem cell transplantation from unmanipulated Haploidentical and unrelated donors in acute leukemia. J Hematol Oncol. 2017;10:24.
   PubMed Web of Science ®Google Scholar
• Lorentino F, Labopin M, Bernardi M, et al. Comparable outcomes of Haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018;93:1236–1244.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu QF, Xu LP, et al. Haploidentical versus matched-sibling transplant in adults with Philadelphia-Negative high-risk acute Lymphoblastic leukemia: A Biologically phase III randomized study. Clin Cancer Res. 2016;22:3467–3476.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang HX, Lai YR, et al. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia. 2016;30:2055–2063.
   PubMed Web of Science ®Google Scholar
• Arcuri LJ, Aguiar MTM, Ribeiro AAF, et al. Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: A Systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019;25:2422–2430.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Bacigalupo A, Rambaldi A, et al. Haploidentical stem cell transplantation With Posttransplant cyclophosphamide Therapy vs other donor transplantations in adults With hematologic cancers: A Systematic review and meta-analysis. JAMA Oncol. 2019;5:1739–1748.
   PubMed Web of Science ®Google Scholar
• Wachsmuth LP, Patterson MT, Eckhaus MA, et al. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129:2357–2373.
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Sun Y, Labopin M, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in Haploidentical transplant. Haematologica. 2017;102:401–410.
   PubMed Web of Science ®Google Scholar
• Tang F, Xu Y, Chen H, et al. Comparison of the clinical outcomes of hematologic malignancies after myeloablative Haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese bone marrow transplantation registry group (CBMTRG). Sci China Life Sci. 2020;63(4):571–581.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Dominietto A, Ghiso A, et al. Unmanipulated Haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplant. 2015;50(Suppl 2):S37–S39.
   PubMed Web of Science ®Google Scholar